Digital therapeutics (DTx) face unpredictable requirements or standards in Europe for much of the development and commercialization pathway, including marketing authorization, value assessment, reimbursement and pricing, the European Federation of Pharmaceutical Industries and Associations says in a report in which it recommends how to improve access to these technologies.
While there has been some progress in integrating DTx into market access and care pathways, only Belgium and Germany offer value assessment, reimbursement and funding pathways, with more intermittent offerings...